UBS Group
HALO icon

UBS Group’s Halozyme HALO Stock Holding History

UBS Group’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-80,000
Closed -$1.81M – 8499
2015
Q2 		$1.81M Buy
80,000
+5,000
+7% +$87.9K ﹤0.01% 3077
2015
Q1 		$1.07M Buy
+75,000
New +$1.08M ﹤0.01% 3506

Other funds holding HALO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

UBS Group's HALO Position: Q2 2026 in Review

UBS Group increased its Halozyme (HALO) stake by 63% in Q2 2026, buying an estimated $39.4M and bringing the position to 1,492,224 shares worth $117M. The position accounts for 0.01% of the portfolio, ranked #1013.

UBS Group first reported a position in HALO in Q4 2014 and has held it in 47 quarters since. The position peaked at $216M in Q3 2025. 672 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • UBS Group held 1,492,224 shares of Halozyme worth $117M as of Q2 2026.
  • UBS Group bought 578,221 Halozyme shares in Q2 2026, an estimated $39.4M.
  • Halozyme made up 0.01% of UBS Group's portfolio in Q2 2026, its #1013 holding.
  • UBS Group first reported a position in Halozyme in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's Halozyme position peaked at $216M in Q3 2025.
  • 672 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.